Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study
- PMID: 28359798
- DOI: 10.1016/S2213-2600(17)30110-8
Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study
Abstract
Background: The Streptococcus pneumoniae Invasive Disease network (SpIDnet) actively monitors populations in nine sites in seven European countries for invasive pneumococcal disease. Five sites use 13-valent pneumococcal conjugate vaccine (PCV13) alone and four use the ten-valent PCV (PCV10) and PCV13. Vaccination uptake is greater than 90% in six sites and 67-78% in three sites. We measured the effects of introducing high-valency PCVs on the incidence of invasive pneumococcal disease in children younger than 5 years.
Methods: We compared the incidence of invasive pneumococcal disease in each of the 4 years after the introduction of PCV13 alone or PCV10 and PCV13 with the average incidence during the preceding period of heptavalent PCV (PCV7) use, overall and by serotype category. We calculated incidence rate ratios (IRRs) and 95% CIs for each year and pooled the values for all sites in a random effects meta-analysis.
Findings: 4 years after the introduction of PCV13 alone or PCV10 and PCV13, the pooled IRR was 0·53 (95% CI 0·43-0·65) for invasive pneumococcal disease in children younger than 5 years caused by any serotype, 0·16 (0·07-0·40) for disease caused by PCV7 serotypes, 0·17 (0·07-0·42) for disease caused by 1, 5, and 7F serotypes, and 0·41 (0·25-0·69) for that caused by 3, 6A and 19A serotypes. We saw a similar pattern when we restricted the analysis to sites where only PCV13 was used. The pooled IRR for invasive pneumococcal disease caused by non-PCV13 serotypes was 1·62 (1·09-2·42).
Interpretation: The incidence of invasive pneumococcal disease caused by all serotypes decreased due to a decline in the incidence of vaccine serotypes. By contrast, that of invasive pneumococcal disease caused by non-PCV13 serotypes increased, which suggests serotype replacement. Long-term surveillance will be crucial to monitor the further effects of PCV10 and PCV13 vaccination programmes in young children.
Funding: European Centre for Disease Prevention and Control, Czech National Institute of Public Health, French National Agency for Public Health, Irish Health Services Executive, Norwegian Institute of Public Health, Public Health Agency of Catalonia, Public Health Department of Community of Madrid, Navarra Hospital Complex, Public Health Institute of Navarra, CIBER Epidemiology and Public Health, Institute of Health Carlos III, Public Health Agency of Sweden, and NHS Scotland.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
-
The future of paediatric pneumococcal conjugate vaccines.Lancet Respir Med. 2017 Aug;5(8):605-606. doi: 10.1016/S2213-2600(17)30111-X. Epub 2017 Mar 27. Lancet Respir Med. 2017. PMID: 28359797 No abstract available.
Similar articles
-
Pneumococcal serotype evolution in Western Europe.BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. BMC Infect Dis. 2015. PMID: 26468008 Free PMC article. Review.
-
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.Lancet Infect Dis. 2015 May;15(5):535-43. doi: 10.1016/S1473-3099(15)70044-7. Epub 2015 Mar 20. Lancet Infect Dis. 2015. PMID: 25801458
-
Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.Lancet Infect Dis. 2021 Jan;21(1):127-136. doi: 10.1016/S1473-3099(20)30173-0. Epub 2020 Jul 20. Lancet Infect Dis. 2021. PMID: 32702303
-
Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.Clin Infect Dis. 2017 Jan 15;64(2):175-183. doi: 10.1093/cid/ciw720. Epub 2016 Oct 21. Clin Infect Dis. 2017. PMID: 27986682
-
Streptococcus pneumoniae serotype 19A: worldwide epidemiology.Expert Rev Vaccines. 2017 Oct;16(10):1007-1027. doi: 10.1080/14760584.2017.1362339. Epub 2017 Aug 28. Expert Rev Vaccines. 2017. PMID: 28783380 Review.
Cited by
-
Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths.Vaccines (Basel). 2021 May 8;9(5):474. doi: 10.3390/vaccines9050474. Vaccines (Basel). 2021. PMID: 34066697 Free PMC article.
-
Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged < 5 Years: A Prospective Study.Vaccines (Basel). 2020 Jul 15;8(3):387. doi: 10.3390/vaccines8030387. Vaccines (Basel). 2020. PMID: 32679762 Free PMC article.
-
Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study.Lancet Infect Dis. 2019 Jul;19(7):759-769. doi: 10.1016/S1473-3099(19)30297-X. Epub 2019 Jun 10. Lancet Infect Dis. 2019. PMID: 31196809 Free PMC article.
-
Respiratory infections in the Asia-Pacific region.Respirology. 2017 Aug;22(6):1061. doi: 10.1111/resp.13077. Epub 2017 May 24. Respirology. 2017. PMID: 28544469 Free PMC article. No abstract available.
-
Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.Hum Vaccin Immunother. 2017 Oct 3;13(10):2307-2315. doi: 10.1080/21645515.2017.1343773. Epub 2017 Jul 12. Hum Vaccin Immunother. 2017. PMID: 28700264 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical